To determine the efficacy of oral nimodipine in reducing cerebral infarction and poor outcomes following subarachnoid hemorrhage.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Double-blind, placebo-controlled, randomized trial of 554 patients at 4 regional neurosurgical units in the United Kingdom.
Patients were randomized to receive placebo or nimodipine 60 mg given orally every four hours for 21 days. All patients were followed for up to three months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Incidence of cerebral infarction at 3 months.|
|Secondary||Incidence of poor outcome (dead, vegetative state, and severe disability).|